Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats.
The nicotinic alpha7 agonist dimethoxybenzilidene anabaseine (DMXB) and cholinesterase inhibitor tetrahydroaminoacridine (THA) were investigated in a trans-synaptic model for neocortical atrophy and degeneration following nucleus basalis lesions. Bilateral lesions reduced parietal neuronal density in layers II-V 8 months later. DMXB administered i.p. daily to rats for 3 months attenuated this loss in layers II-V at a 1 mg/kg i.p. dose. A lower, 0.2 mg/kg i.p. dose, was neuroprotective in layer IV only. THA (1 mg/kg i.p.) also protected against neocortical Nissl-staining deficits.
Meyer
E M
EM
Department of Pharmacology and Therapeutics, Box 100267, University Florida College of Medicine, Gainesville, FL 32610, USA.
King
M A
MA
Meyers
C
C
D000818:Animals; D001597:Benzylidene Compounds / Q000494:pharmacology*; D002452:Cell Count / Q000187:drug effects; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D010296:Parietal Lobe / Q000187:drug effects / Q000473:pathology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013377:Substantia Innominata / Q000502:physiology*; D013619:Tacrine / Q000494:pharmacology*
D001597:Benzylidene Compounds; D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D018733:Nicotinic Antagonists; D011725:Pyridines; D013619:Tacrine; C088936:3-(2,4-dimethoxybenzylidene)anabaseine